# Hansoh Pharmaceutical

Source: https://onco.cc/companies/hansoh-pharma/  
OnCo record `hansoh-pharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Hansoh is a Chinese pharmaceutical group whose EGFR inhibitor aumolertinib (Ameile in China, Aumseqa in the EU) became the first China-originated lung cancer pill authorised by the European Commission in 2026.

## Summary

Hansoh Pharmaceutical, based in Lianyungang, Jiangsu, and listed in Hong Kong as 3692.HK, is a Chinese pharmaceutical group whose EGFR inhibitor aumolertinib, sold as Ameile in China and Aumseqa in the European Union, became the first China-originated lung cancer tablet authorised by the European Commission in 2026. Aumolertinib is a third-generation EGFR kinase inhibitor approved by the NMPA in 2020 and by the EU in 2026 for EGFR-mutant non-small-cell lung cancer, and the company has out-licensed antibody-drug conjugate and GLP-1 assets to GSK and Merck. OnCo links it to the aumolertinib drug record. Whether a European approval can win share from the established third-generation EGFR drug is the open question. Aumolertinib has its own page. The B7-H4 (HS-20089) and B7-H3 (HS-20093) antibody-drug conjugates were licensed to GSK in 2023 for $85 million and $185 million upfront, and the GLP-1 agreements with Merck & Co. sit outside oncology; the company was founded in 1995 and is run by Zhong Huijuan, one of the world's wealthiest self-made women.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Also known as: Hansoh; Hansoh Pharma; Hansoh Pharmaceutical Group; 翰森制药; hansoh
- Tags: china
- HQ: Lianyungang, Jiangsu
- Type: pharma
- Website: https://www.hspharm.com
- Ticker: 3692.HK

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Hansoh_Pharmaceutical
- Official website: https://www.hspharm.com/

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Aumolertinib](https://onco.cc/drugs/aumolertinib/), [Flumatinib](https://onco.cc/drugs/flumatinib/), [HS-20089](https://onco.cc/drugs/hs-20089/), [HS-20093](https://onco.cc/drugs/hs-20093/), [HS-20117](https://onco.cc/drugs/hs-20117/)
- companies: [GSK](https://onco.cc/companies/gsk/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/)
- trials: [A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.](https://onco.cc/trials/nct07283367/), [A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamo](https://onco.cc/trials/nct07824882/), [A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-S](https://onco.cc/trials/nct07464327/), [A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer](https://onco.cc/trials/nct04951635/), [A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Pat](https://onco.cc/trials/nct07822542/), [A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06147570/), [A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy](https://onco.cc/trials/nct07468851/), [A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer](https://onco.cc/trials/nct06526624/), [A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06417008/), [AENEAS](https://onco.cc/trials/aeneas/), [Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations](https://onco.cc/trials/nct04687241/), [ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas](https://onco.cc/trials/nct05830123/), [ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors](https://onco.cc/trials/nct06007729/), [ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer](https://onco.cc/trials/nct06498479/), [Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mut](https://onco.cc/trials/nct04923906/), [HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer](https://onco.cc/trials/nct06855069/), [HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer](https://onco.cc/trials/nct06014190/), [HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors](https://onco.cc/trials/nct06112704/), [Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors](https://onco.cc/trials/nct05367778/), [Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)](https://onco.cc/trials/nct05435248/), [Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC](https://onco.cc/trials/nct07754123/), [Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure](https://onco.cc/trials/nct06935409/)

---
JSON: https://onco.cc/api/v1/entities/hansoh-pharma.json